View in EDS HTML Full Text PDF Full Text

ER status conversion and subsequent treatment: an assessment of negative ER expression detected by 18F-FES PET in metastatic breast cancer patients with ER-positive primary tumors.

Saved in:
Bibliographic Details
Title: ER status conversion and subsequent treatment: an assessment of negative ER expression detected by 18F-FES PET in metastatic breast cancer patients with ER-positive primary tumors.
Authors: You S; Department of Breast and Urological Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China., Xie Y; Department of Breast and Urological Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.; Department of Medical Oncology, Zhongshan Hospital Fudan University, Shanghai, China., Ji M; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.; Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, China.; Center for Biomedical Imaging, Fudan University, Shanghai, China.; Shanghai Engineering Research Center of Molecular Imaging Probes, Shanghai, China., Liu C; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.; Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, China.; Center for Biomedical Imaging, Fudan University, Shanghai, China.; Shanghai Engineering Research Center of Molecular Imaging Probes, Shanghai, China., Zhao Y; Department of Breast and Urological Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China., Gong C; Department of Breast and Urological Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China., Hu S; Department of Breast and Urological Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China., Li Y; Department of Breast and Urological Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China., Yang Z; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.; Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, No. 270, Dongan Road, Shanghai 200032, China.; Center for Biomedical Imaging, Fudan University, Shanghai, China.; Shanghai Engineering Research Center of Molecular Imaging Probes, Shanghai, China., Wang B; Department of Breast and Urological Medical Oncology, Fudan University Shanghai Cancer Center, 130 Dongan Road, Xuhui District, Shanghai 200032, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Source: Therapeutic advances in medical oncology [Ther Adv Med Oncol] 2023 Dec 15; Vol. 15, pp. 17588359231216093. Date of Electronic Publication: 2023 Dec 15 (Print Publication: 2023).
Publication Type: Journal Article
Journal Info: Publisher: Sage Country of Publication: England NLM ID: 101510808 Publication Model: eCollection Cited Medium: Print ISSN: 1758-8340 (Print) Linking ISSN: 17588340 NLM ISO Abbreviation: Ther Adv Med Oncol Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 38107829
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: ER status conversion and subsequent treatment: an assessment of negative ER expression detected by 18F-FES PET in metastatic breast cancer patients with ER-positive primary tumors.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22You+S%22">You S</searchLink>; Department of Breast and Urological Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.<br /><searchLink fieldCode="AU" term="%22Xie+Y%22">Xie Y</searchLink>; Department of Breast and Urological Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.; Department of Medical Oncology, Zhongshan Hospital Fudan University, Shanghai, China.<br /><searchLink fieldCode="AU" term="%22Ji+M%22">Ji M</searchLink>; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.; Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, China.; Center for Biomedical Imaging, Fudan University, Shanghai, China.; Shanghai Engineering Research Center of Molecular Imaging Probes, Shanghai, China.<br /><searchLink fieldCode="AU" term="%22Liu+C%22">Liu C</searchLink>; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.; Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, China.; Center for Biomedical Imaging, Fudan University, Shanghai, China.; Shanghai Engineering Research Center of Molecular Imaging Probes, Shanghai, China.<br /><searchLink fieldCode="AU" term="%22Zhao+Y%22">Zhao Y</searchLink>; Department of Breast and Urological Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.<br /><searchLink fieldCode="AU" term="%22Gong+C%22">Gong C</searchLink>; Department of Breast and Urological Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.<br /><searchLink fieldCode="AU" term="%22Hu+S%22">Hu S</searchLink>; Department of Breast and Urological Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.<br /><searchLink fieldCode="AU" term="%22Li+Y%22">Li Y</searchLink>; Department of Breast and Urological Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.<br /><searchLink fieldCode="AU" term="%22Yang+Z%22">Yang Z</searchLink>; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.; Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, No. 270, Dongan Road, Shanghai 200032, China.; Center for Biomedical Imaging, Fudan University, Shanghai, China.; Shanghai Engineering Research Center of Molecular Imaging Probes, Shanghai, China.<br /><searchLink fieldCode="AU" term="%22Wang+B%22">Wang B</searchLink>; Department of Breast and Urological Medical Oncology, Fudan University Shanghai Cancer Center, 130 Dongan Road, Xuhui District, Shanghai 200032, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101510808%22">Therapeutic advances in medical oncology</searchLink> [Ther Adv Med Oncol] 2023 Dec 15; Vol. 15, pp. 17588359231216093. <i>Date of Electronic Publication: </i>2023 Dec 15 (<i>Print Publication: </i>2023).
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Sage%22">Sage </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101510808 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Print <i>ISSN: </i>1758-8340 (Print) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2217588340%22">17588340 </searchLink><i>NLM ISO Abbreviation: </i>Ther Adv Med Oncol <i>Subsets: </i>PubMed not MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=38107829
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1177/17588359231216093
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 17588359231216093
    Titles:
      – TitleFull: ER status conversion and subsequent treatment: an assessment of negative ER expression detected by 18F-FES PET in metastatic breast cancer patients with ER-positive primary tumors.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: You S
      – PersonEntity:
          Name:
            NameFull: Xie Y
      – PersonEntity:
          Name:
            NameFull: Ji M
      – PersonEntity:
          Name:
            NameFull: Liu C
      – PersonEntity:
          Name:
            NameFull: Zhao Y
      – PersonEntity:
          Name:
            NameFull: Gong C
      – PersonEntity:
          Name:
            NameFull: Hu S
      – PersonEntity:
          Name:
            NameFull: Li Y
      – PersonEntity:
          Name:
            NameFull: Yang Z
      – PersonEntity:
          Name:
            NameFull: Wang B
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 15
              M: 12
              Text: 2023 Dec 15
              Type: published
              Y: 2023
          Identifiers:
            – Type: issn-print
              Value: 1758-8340
          Numbering:
            – Type: volume
              Value: 15
          Titles:
            – TitleFull: Therapeutic advances in medical oncology
              Type: main
ResultId 1